Clinical Trial Update: A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy [Phase 4]

View source ↗

Summary

A single-arm pilot Phase 4 study evaluating tislelizumab plus anlotinib in advanced driver-negative non-small cell lung cancer after progression on immunotherap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | Conditions: Advanced NSCLC | Phase 4 | Status: NOT_YET_RECRUITING